Compare SFM & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFM | GKOS |
|---|---|---|
| Founded | 2002 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.0B |
| IPO Year | 2013 | 2015 |
| Metric | SFM | GKOS |
|---|---|---|
| Price | $76.13 | $118.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 14 |
| Target Price | $98.89 | ★ $133.07 |
| AVG Volume (30 Days) | ★ 2.0M | 652.5K |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.60 | N/A |
| EPS | ★ 5.31 | N/A |
| Revenue | ★ $8,806,159,000.00 | $507,442,000.00 |
| Revenue This Year | $9.05 | $23.30 |
| Revenue Next Year | $7.46 | $27.43 |
| P/E Ratio | $14.52 | ★ N/A |
| Revenue Growth | 14.08 | ★ 32.33 |
| 52 Week Low | $64.75 | $73.16 |
| 52 Week High | $182.00 | $130.23 |
| Indicator | SFM | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 47.70 | 60.81 |
| Support Level | $75.26 | $104.72 |
| Resistance Level | $82.28 | $123.16 |
| Average True Range (ATR) | 2.51 | 4.51 |
| MACD | -0.39 | 1.61 |
| Stochastic Oscillator | 41.88 | 80.37 |
Sprouts Farmers Market Inc offers a specialty grocery experience featuring an open layout with fresh produce at the heart of the store. Sprouts inspire wellness naturally with a carefully curated assortment products paired with purpose-driven people. The company continues to bring products made with lifestyle-friendly ingredients such as organic, plant-based, and gluten-free. It approximately has 407 stores in nearly 23 states. The Company has one operating segment that is healthy grocery stores.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.